- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03465475
Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode
August 24, 2021 updated by: Yusuf Ziya ÇOLAK, Inonu University
Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode With Maquet Flow-i Anaesthesia Machine
Inhalation agents constitute the major part of anesthetic drug costs (20% - 25%) and a significant portion of the applied inhalation agents are thrown into the atmosphere through the waste gas system without being absorbed by the patient.
The amount of waste gas is directly correlated to the fresh gas flow (FGF).
Reducing the TGA during general anesthesia reduces the consumption of inhalant agents and contributes to the reduction of greenhouse gas pollution.
Risks such as hypoxia, hypercapnia, inadequate depth of anesthesia and potential toxic gas accumulation were associated with low flow anesthesia, but the patient was provided with adequate safety by following pulse oximetry, capnography, FiO2 and anesthetic gas analysis.
We aimed to perform anesthetic cost analysis and patient security in automated gas control mode (AGC).
Study Overview
Status
Completed
Conditions
Detailed Description
After the ethical approvel 60 adult patients scheduled for hepatectomy will be taken to study.
Patients will be monitored after they are taken to the operating room (ECG, NIBP, SpO2, Body Temp, BIS, NIRS, PVI, PI, ORI).
After the anesthesia induction and tarakeal entubation, first twenty patient will take 300 mL fresh gas flow with AGC mode (group 1), Second twenty patient will take 600 mL fresh gas flow with AGC mode (group 2), third twenty patient will take 600 mL fresh gas flow with manually.
Hemodynamic and gas consumption data will be recorded.
An operating room will be reserved for this study.
Study Type
Observational
Enrollment (Actual)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Malatya, Turkey, 44280
- Inonu Univercity
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing hepatectomy operation
Description
Inclusion Criteria:
- Adult patients undergoing hepatectomy with general anesthesia
Exclusion Criteria:
- Essential data missing
- Patient participating in other research projects
- Drug allergy
- Anesthetic complication story
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Group 1
The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
|
|
Group 2
The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
|
|
Group 3
The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of used anesthetic gas (desflurane)
Time Frame: Through study completion, an average of 2 month
|
Amount of used desflurane will be determined in milliliter by anesthesia machine (Maquet Flow i40) for each patient.
|
Through study completion, an average of 2 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: Through study completion, an average of 2 month
|
Heart rate/min
|
Through study completion, an average of 2 month
|
|
Mean arterial pressure
Time Frame: Through study completion, an average of 2 month
|
Mean arterial pressure (mm/Hg)
|
Through study completion, an average of 2 month
|
|
Peripheral oxygen saturation
Time Frame: Through study completion, an average of 2 month
|
Peripheral oxygen saturation (%)
|
Through study completion, an average of 2 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yusuf Z Çolak, MD, Investigator
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2018
Primary Completion (Actual)
October 30, 2020
Study Completion (Actual)
March 1, 2021
Study Registration Dates
First Submitted
February 1, 2018
First Submitted That Met QC Criteria
March 13, 2018
First Posted (Actual)
March 14, 2018
Study Record Updates
Last Update Posted (Actual)
August 25, 2021
Last Update Submitted That Met QC Criteria
August 24, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- Inonu uni
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety Issues
-
Shenyang Sunshine Pharmaceutical Co., LTD.Recruiting
-
Chulalongkorn UniversityNot yet recruiting
-
IC-MedTech CorporationCompleted
-
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics...Active, not recruiting
-
Mansoura UniversityCompleted
-
Showa Inan General HospitalCompleted
-
Asmaa Elwan Mohammed HassanCompleted
-
Hadassah Medical OrganizationGals Bio Ltd.Withdrawn
-
Federico II UniversityCompleted
-
Institute of Nuclear Energy Research, TaiwanCompleted